Financial Data and Key Metrics Changes - In 2025, the company's revenue reached RMB 73.4 billion, representing a year-over-year increase of 26.3% [7][18] - Non-IFRS profit totaled RMB 6.5 billion, up 36.3% year-over-year, with a non-IFRS profit margin of 8.9% [8][25] - The fourth quarter revenue was RMB 21 billion, reflecting a year-over-year increase of 27.4% [7][18] Business Line Data and Key Metrics Changes - Direct sales revenue reached RMB 16.9 billion in 2025, a year-over-year increase of 24.8%, accounting for 82.9% of total revenue [19] - Service revenue was RMB 12.6 billion, up 34.1% year-over-year, representing 17.1% of total revenue [19] - The company introduced over 100 new drugs during the year, a significant increase from 30 in 2024 [8] Market Data and Key Metrics Changes - The annual active user accounts reached approximately 200 million, with an addition of 34 million compared to the previous year [18] - The company established more than 300 self-operated pharmacies nationwide, integrating them with on-demand retail services [12] Company Strategy and Development Direction - The company aims to deepen its presence across key healthcare segments through an omnichannel approach and AI-powered healthcare services [6] - Future growth will focus on expanding partnerships with pharmaceutical companies and enhancing the user experience through innovative health solutions [9][15] - The company plans to leverage its supply chain strengths and direct sales capabilities to maintain leadership in the healthcare retail market [15][26] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in the company's growth potential, citing a large market size of RMB 3 trillion-4 trillion for the pharmaceutical sector [30] - The company is committed to enhancing user experiences and improving cost efficiency through AI-powered health service scenarios [26] - Management acknowledged the competitive landscape but emphasized the company's strengths in supply chain management and product quality [42] Other Important Information - The company has invested in AI technologies, with Dr. Dawei completing hundreds of millions of user interactions and achieving a 98% satisfaction rate [21][37] - The fulfillment expense ratio was 10.4%, and the selling and marketing expense ratio remained stable at 5.2% [23] Q&A Session Summary Question: Near term and three-year middle term prospects - Management highlighted the growth potential in the pharmaceutical sector and the importance of expanding product offerings and partnerships [29][34] Question: Competition landscape - Management expressed confidence in standing out among competitors due to strong supply chain management and product quality [42] Question: Plans for brick-and-mortar stores and M&A - Management clarified that there are no plans for large-scale M&A and emphasized a cautious approach to offline practices [48][52] Question: Progress of AI applications - Management discussed the positive outcomes from AI technologies and the potential for future commercialization [56][60]